Incyte Corp
XMUN:ICY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Incyte Corp
XMUN:ICY
|
US |
|
N
|
NICE Holdings Co Ltd
KRX:034310
|
KR |
Intrinsic Value
The intrinsic value of 
Incyte Corp (ICY) under the Base Case is 98.6 EUR per share.
Compared with the current market price of 103.4 EUR, the stock appears
Overvalued by 5% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Incyte Does
Incyte Corp is a biopharmaceutical company that discovers, develops, and sells prescription medicines, mainly for cancer and immune-related diseases. Its best-known products include treatments used by specialists in oncology and dermatology, where doctors prescribe the drugs to patients with conditions such as blood cancers, graft-versus-host disease, and inflammatory skin disorders.
- Headquarters
- United States of America US
- Employees
- 2 844
- IPO date
- Dec 6, 1993
Incyte has no economic moat
Incyte’s medicines face other treatments that doctors and patients can choose instead, and customers generally are not locked into using the company’s products. Patents can hold off copies for a time, but they do not protect the business indefinitely as other drugs compete for the same patients.
Read the full moat analysis
Revenue & Expenses Breakdown
Incyte Corp
Earnings Waterfall
Incyte Corp
The intrinsic value for Incyte Corp (ICY) under the Base Case is 98.6 EUR.
Compared with the current market price of 103.4 EUR, the stock appears Overvalued by 5% .